Search

Kura Oncology Inc

Fermé

SecteurSoins de santé

11.68 0.78

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.2

Max

12.19

Chiffres clés

By Trading Economics

Revenu

5M

-68M

Ventes

2.6M

21M

BPA

-0.77

Marge bénéficiaire

-327.331

Employés

260

EBITDA

7M

-66M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+136.26% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

154M

1B

Ouverture précédente

10.9

Clôture précédente

11.68

Sentiment de l'Actualité

By Acuity

61%

39%

276 / 339 Classement par Healthcare

Kura Oncology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2026, 20:08 UTC

Social Media

Kura Oncology Inc shares are advancing today, supported by increased retail commentary, despite pulling back from a session high earlier in the session.

16 sept. 2026, 20:10 UTC

Kura Oncology Inc shares fell sharply after an early spike, closing significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept. 2026, 22:02 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from a low to a notable high during the session. No specific news was identified.

14 sept. 2026, 20:13 UTC

Kura Oncology Inc shares are higher in after-market hours, though no specific news was identified. The price remains below its 20-day moving average.

10 sept. 2026, 20:03 UTC

Social Media

Kura Oncology Inc shares are lower, continuing a three-day decline despite increasing sales and the approval of its menin inhibitor, KOMZIFTI.

9 sept. 2026, 22:41 UTC

Kura Oncology Inc shares are rising in after-market trading, reflecting positive momentum in the biotechnology sector despite earlier session declines.

8 sept. 2026, 20:02 UTC

News
Social Media

Kura Oncology Inc shares are lower today, influenced by declines in the Biotechnology sector despite the appointment of a new Chief Financial Officer.

3 sept. 2026, 19:47 UTC

Kura Oncology Inc shares are lower today, with no specific news driving the decline. Earlier, the stock rebounded from a session high.

2 sept. 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting strength amid weaker-than-expected job growth reported by ADP.

28 août 2026, 20:08 UTC

Kura Oncology Inc shares are lower today, reflecting broader market trends and rising U.S. Treasury yields amid concerns over inflation and monetary policy.

27 août 2026, 23:46 UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

26 août 2026, 23:41 UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

25 août 2026, 23:06 UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

24 août 2026, 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

21 août 2026, 22:56 UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

20 août 2026, 23:16 UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

19 août 2026, 19:21 UTC

Social Media

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

18 août 2026, 23:06 UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

17 août 2026, 22:51 UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 août 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

13 août 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

12 août 2026, 23:01 UTC

News
Social Media

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

10 août 2026, 19:43 UTC

Event
News

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

7 août 2026, 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 août 2026, 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5 août 2026, 19:26 UTC

News

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4 août 2026, 19:36 UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3 août 2026, 23:01 UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31 juil. 2026, 21:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30 juil. 2026, 19:49 UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

Comparaison

Variation de prix

Kura Oncology Inc prévision

Objectif de Prix

By TipRanks

136.26% hausse

Prévisions sur 12 Mois

Moyen 26.461 USD  136.26%

Haut 40 USD

Bas 12.15 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

10

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

276 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat